Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
Left ventricular hypertrophy (LVH) is an established predictor of poor cardiovascular outcomes, while increases in left ventricular mass indexed (LVMi) have been independently associated with all-cause mortality and sudden death. Sodium-glucose transport protein 2 inhibitors (SGLT2i) have shown marked cardiovascular and renal benefits in patients with type 2 diabetes (T2D).
The EMPA-HEART CardioLink-6 study investigated that sodium-glucose cotransporter-2 inhibition for 6 months with empagliflozin was associated with a significant reduction in LVMi. In this sub-analysis, the study published in Cardiovascular Diabetology evaluated whether baseline LVMi may influence how empagliflozin affects cardiac reverse remodelling.
A total of 97 patients with type 2 diabetes and coronary artery disease were randomized to empagliflozin (10 mg/d) or matching placebo for 6 months. The study cohort was divided into those whose baseline LVMi was ≤ 60 g/m2 and those who had a baseline LVMi > 60 g/m2. Subgroup comparisons were conducted using a linear regression model adjusted for baseline values (ANCOVA) that included an interaction term between LVMi subgroup and treatment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.